切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2026, Vol. 14 ›› Issue (03) : 207 -211. doi: 10.3877/cma.j.issn.2095-655X.2026.03.009

病例诊断思维

累及多系统的迟发型法布里病一例
张竞文1, 陈咏琪1, 左汉恒2,()   
  1. 1272067 济宁医学院临床医学院
    2272029 济宁医学院附属医院心脏康复与心功能检查科
  • 收稿日期:2026-04-22 出版日期:2026-08-26
  • 通信作者: 左汉恒

A case of delayed-onset Fabry disease involving multiple systems

Jingwen Zhang1, Yongqi Chen1, Hanheng Zuo2,()   

  1. 1College of Clinical Medicine, Jining Medical University, Jining 272067, China
    2Department of Cardiac Rehabilitation and Functional Evaluation, the Affiliated Hospital of Jining Medical University, Jining 272029, China
  • Received:2026-04-22 Published:2026-08-26
  • Corresponding author: Hanheng Zuo
引用本文:

张竞文, 陈咏琪, 左汉恒. 累及多系统的迟发型法布里病一例[J/OL]. 中华诊断学电子杂志, 2026, 14(03): 207-211.

Jingwen Zhang, Yongqi Chen, Hanheng Zuo. A case of delayed-onset Fabry disease involving multiple systems[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2026, 14(03): 207-211.

目的

探讨累及多系统的迟发型法布里病(FD)的临床特征与诊断策略。

方法

回顾性分析2024年8月27日济宁医学院附属医院神经内科收治的1例迟发型FD患者的临床资料及诊治过程,总结其漏诊启示及诊断学特征。

结果

患者男性,60岁,因左手知觉差、左下肢无力14 h就诊。既往有腔隙性脑梗死病史14年,伴耳鸣、蛋白尿14年,左心室肥厚12年。本次入院颅脑MRI示右枕顶叶急性期脑梗死;心脏MRI示左室壁不均匀性增厚(最厚19 mm),余节段初始T1值弥漫性减低;左室侧壁见明显钆延迟强化伴局部T1、T2值增高。基因检测示GLA:c.671A>G(p.Asn224Ser)半合子错义突变;α-半乳糖苷酶A活性[0.97 μmol/(L·h)]降低;生物标记物脱乙酰基-三己糖酰基鞘酯醇(Lyso-Gb3)水平明显升高(48.41 μg/L),尿微量白蛋白1 170.0 mg/L,眼裂隙灯检查见双眼角膜涡状混浊,确诊为FD。患者自首发症状至确诊历时14年,漏诊原因在于多系统受累表现未被溯源整合。

结论

对于不明原因脑卒中、心肌肥厚合并蛋白尿等多系统受累者,应警惕FD可能,需及时行酶学与基因检测。

Objective

To explore the clinical features and diagnostic strategies of delayed-onset Fabry disease (FD) involving multiple systems.

Methods

A retrospective analysis was conducted on the clinical data and treatment process of a patient with delayed-onset FD admitted to the Department of Neurology, the Affiliated Hospital of Jining Medical University on August 27, 2024. The lessons from the diagnostic delay and key diagnostic features were summarized.

Results

A 60-year-old male presented with a 14-hour history of hypoesthesia in the left hand and weakness in the left lower limb. The patient had a history of lacunar cerebral infarction (14 years), tinnitus and proteinuria (14 years), and left ventricular hypertrophy (12 years). On admission, cranial MRI revealed an acute cerebral infarction in the right parieto-occipital lobe. Cardiac MRI revealed non-uniform left ventricular wall thickening (maximal wall thickness of 19 mm), diffuse reduction of native T1 values in the remaining myocardial segments, and marked late gadolinium enhancement (LGE) with localized elevated T1 and T2 values in the left ventricular lateral wall. Genetic testing identified a hemizygous missense variation in the GLA gene: c. 671A>G (p.Asn224Ser). Furthermore, enzymatic activity of α-galactosidase A [0.97 μmol/(L·h)] was decreased, and the biomarker Lyso-Gb3 (48.41 μg/L) was markedly elevated; urinary microalbumin was level 1 170.0 mg/L, and slit-lamp examination revealed bilateral cornea verticillata, confirming the diagnosis of FD. Notably, the patient experienced a diagnostic delay of 14 years from the onset of initial symptoms to definitive diagnosis. The primary reason for this missed diagnosis was the failure to trace and integrate the multisystem manifestations into a unified etiology.

Conclusions

FD should be considered in the differential diagnosis for patients with cryptogenic stroke, left ventricular hypertrophy, and proteinuria. Prompt enzymatic assays and genetic analysis are crucial for early confirmation.

图1 累及多系统的迟发型法布里病患者颅脑及心脏磁共振成像检查图像注:a图T1WI示右侧枕顶叶(红色箭头)、侧脑室周围(绿色箭头)见斑片状低信号;b图T2WI示右侧枕顶叶(红色箭头)、侧脑室周围(绿色箭头)见斑片状高信号;c图SWI序列示右侧顶枕叶少许斑片状出血灶(红色箭头);d图DWI序列示右侧顶枕叶病灶扩散受限呈高信号(红色箭头);e图为表观扩散系数图示右侧顶枕叶呈低信号(绿色箭头);f图磁共振血管成像示右侧颈内动脉虹吸段、左侧大脑后动脉P2段局限性狭窄;g图心脏MRI电影序列示左室壁不均匀性增厚,间隔壁为著;h图心脏MRI灌注成像示左室心尖段侧壁局限性灌注减低;i图心脏MRI延迟强化示左室基底段-心尖段侧壁透壁、心内膜下延迟强化(红色箭头);j图心脏MRI初始T1示左室基底段-心尖段侧壁T1值增高,余节段T1值弥漫性减低;T1WI为T1加权成像;T2WI为T2加权成像;SWI为磁敏感加权成像;DWI为弥散加权成像
图2 累及多系统的迟发型法布里病患者GLA基因突变Sanger测序图像注:a图示c.671A>G(p.Asn224Ser)半合子错义突变(突变位点见红色箭头);b图示正常人群对照基因型(见绿色箭头)
[1]
中国法布雷病专家协作组.中国法布雷病诊疗专家共识(2021年版)[J].中华内科杂志202160(4):321-330.DOI:10.3760/cma.j.cn112138-20201218-01028.
[2]
Hung CLWu YWKuo L,et al.2024 update of the TSOC expert consensus of Fabry disease[J].Acta Cardiol Sin202440(5):544-568.DOI:10.6515/ACS.202409_40(5).20240731A.
[3]
Thomas LSadick N.A case of Fabry disease mimicking hypertrophic cardiomyopathy[J].Heart Lung Circ200413(2):188-190.DOI:10.1016/j.hlc.2004.01.030.
[4]
Saito SOhno KSakuraba H.Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A[J].PLoS One20138(12):e84267.DOI:10.1371/journal.pone.0084267.
[5]
Seo J, Kim M, Hong GR, et al. Fabry disease in patients with hypertrophic cardiomyopathy:a practical approach to diagnosis[J].J Hum Genet201661(9):775-780.DOI:10.1038/jhg.2016.52.
[6]
Lin Z, Zhang X, Liu Y, et al. Screening for Fabry disease in patients with left ventricular hypertrophy in China:a multicenter and prospective study[J].ESC Heart Fail202411(6):4381-4389.DOI:10.1002/ehf2.15065.
[7]
左汉恒,李银平,完颜红心,等.法布雷病家系6例患者临床分析[J].中华心力衰竭和心肌病杂志20259(2):121-128.DOI:10.3760/cma.j.cn101460-20241229-00124.
[8]
Chen XQiu WYe J,et al.Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China[J].J Hum Genet201661(4):345-349.DOI:10.1038/jhg.2015.155.
[9]
潘晓霞,欧阳彦,王朝晖,等.法布里病83例临床病理特点分析[J].中国实用内科杂志201434(3):262-266.
[10]
法布雷病全国专家协作组,中国医药教育协会临床肾脏病学专业委员会.法布雷病多学科联合全程管理路径[J].中华内科杂志202362(8):949-955.DOI:10.3760/cma.j.cn112138-20230218-00095.
[11]
孙明辉,雷旭,李金科,等. "一元论"病因诊断在心率矛盾反应中的临床应用[J/OL].中华诊断学电子杂志20197(1):59-62[2026-04-22].DOI:10.3877/cma.j.issn.2095-655X.2019.01.012.
[12]
Rozenfeld PFeriozzi S.Contribution of inflammatory pathways to Fabry disease pathogenesis[J].Mol Genet Metab2017122(3):19-27.DOI:10.1016/j.ymgme.2017.09.004.
[13]
Fellgiebel AMüller MJGinsberg L.CNS manifestations of Fabry′s disease[J].Lancet Neurol20065(9):791-795.DOI:10.1016/S1474-4422(06)70548-8.
[14]
Cocozza S, Russo C, Pontillo G, et al. Neuroimaging in Fabry disease:current knowledge and future directions[J].Insights Imaging20189(6):1077-1088.DOI:10.1007/s13244-018-0664-8.
[15]
孙中茹,李兆婷,陈艳,等.多模态磁共振成像在法布雷病患者脑损伤评估中的应用研究进展[J].中华内科杂志202564(4):368-372.DOI:10.3760/cma.j.cn112138-20241006-00651.
[16]
Cortés-Saladelafont E, Fernández-Martín J, Ortolano S. Fabry disease and central nervous system involvement:from big to small,from brain to synapse[J].Int J Mol Sci202324(6):5246.DOI:10.3390/ijms24065246.
[17]
Scaravilli ACapasso SUgga L,et al.Clinical and pathophysiologic correlates of basilar artery measurements in Fabry disease[J].AJNR Am J Neuroradiol202445(11):1670-1677.DOI:10.3174/ajnr.A8403.
[18]
Manara RCarlier RYRighetto S,et al.Basilar artery changes in Fabry disease[J].AJNR Am J Neuroradiol201738(3):531-536.DOI:10.3174/ajnr.A5069.
[19]
中华医学会心血管病学分会,中华心血管病杂志编辑委员会.成人法布雷病心肌病诊断与治疗中国专家共识[J].中华心血管病杂志202452(2):128-136.DOI:10.3760/cma.j.cn112148-20231008-00263.
[20]
Favalli V, Disabella E, Molinaro M, et al. Genetic screening of Anderson-Fabry disease in probands referred from multispecialty clinics[J].J Am Coll Cardiol201668(10):1037-1050.DOI:10.1016/j.jacc.2016.05.090.
[21]
Camporeale ADiano ATondi L,et al.Cardiac magnetic resonance features of Fabry disease:from early diagnosis to prognostic stratification[J].Rev Cardiovasc Med202223(5):177.DOI:10.31083/j.rcm2305177.
[22]
Sado DMWhite SKPiechnik SK,et al.Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping[J].Circ Cardiovasc Imaging20136(3):392-398.DOI:10.1161/CIRCIMAGING.112.000070.
[23]
Messroghli DRMoon JCFerreira VM,et al.Clinical recommendations for cardiovascular magnetic resonance mapping of T1,T2,T2* and extracellular volume:a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J].J Cardiovasc Magn Reson201719(1):75.DOI:10.1186/s12968-017-0389-8.
[24]
Camporeale APieroni MPieruzzi F,et al. Predictors of clinical evolution in prehypertrophic Fabry disease[J].Circ Cardiovasc Imaging201912(4):e008424.DOI:10.1161/CIRCIMAGING.118.008424.
[25]
Camporeale AMoroni FLazzeroni D,et al.Trabecular complexity as an early marker of cardiac involvement in Fabry disease[J].Eur Heart J Cardiovasc Imaging202223(2):200-208.DOI:10.1093/ehjci/jeaa354.
[26]
Karur GRMathur SMorel CF,et al.Increased spread of native T1 values assessed with MRI as a marker of cardiac involvement in Fabry disease[J].AJR Am J Roentgenol2021216(2):355-361.DOI:10.2214/AJR.20.23102.
[1] 李运帷, 段晓春, 齐文涛. 重型颅脑损伤术后创伤性脑梗死的危险因素与发病机制研究进展[J/OL]. 中华神经创伤外科电子杂志, 2025, 11(06): 398-404.
[2] 宋丽娜, 安鹏. CTP跨时相放射组学模型预测急性脑梗死溶栓后出血转化风险[J/OL]. 中华脑科疾病与康复杂志(电子版), 2025, 15(06): 342-351.
[3] 李小萍, 张清芳, 李东霞, 陈文生, 王坤, 王诚婷, 龙建军. 基于HIF-1α/VEGF通路探讨经颅交流电刺激联合运动训练对脑梗死后肢体痉挛大鼠功能恢复的影响与机制研究[J/OL]. 中华脑科疾病与康复杂志(电子版), 2025, 15(05): 261-267.
[4] 朱华, 邓一军. 颈内动脉粥样硬化斑块的三维MR血管壁成像特征对急性脑梗死的预测效能研究[J/OL]. 中华介入放射学电子杂志, 2026, 14(01): 89-96.
[5] 黄虎, 宋春杰, 韩远远. 脑小血管病总负荷和甘油三酯葡萄糖体质量指数对老年脑梗死患者溶栓后早期神经功能恶化的预测价值[J/OL]. 中华老年病研究电子杂志, 2025, 12(04): 14-20.
[6] 吴波娜, 曹德峰, 吴婧. 急性小动脉闭塞型脑梗死患者血压昼夜节律改变与早期神经功能恶化的相关性研究[J/OL]. 中华卫生应急电子杂志, 2026, 12(01): 6-9.
[7] 郭祥林, 颜虎. 急诊绿色通道下阿替普酶与重组人组织型纤溶酶原激活剂溶栓救治急性脑梗死的效果比较研究[J/OL]. 中华卫生应急电子杂志, 2026, 12(01): 21-25.
[8] 王春伟, 杜青. 急性脑梗死患者THRIVE评分、NLR值、血清ACA、GFAP水平与静脉溶栓预后的相关性[J/OL]. 中华卫生应急电子杂志, 2025, 11(06): 325-328.
[9] 刘心怡, 林晓晖, 陈荣城, 林进皇, 林定来, 易婷玉, 吴燕敏, 陈文伙. 5G+智慧急救系统在急性大血管闭塞性缺血性脑卒中救治中的意义[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(03): 294-300.
[10] 陈若梦, 苏旭东, 周晓伟, 张坤, 仇福成, 董慈, 陈子墨, 刘佳慧, 王浩然, 王红霞, 刘晓云. 脑机接口康复训练联合传统康复治疗对急性期脑梗死短期运动功能的改善效果[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 126-132.
[11] 于玲, 秦伟, 徐霁华, 胡秀朝, 杨磊, 胡文立. 急性小脑梗死的临床影像学特征[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 133-138.
[12] 李丽娜, 彭滢, 巩俪, 郑志东. 血清脂蛋白(a)、载脂蛋白B/载脂蛋白A1比值与急性脑梗死阿替普酶静脉溶栓治疗预后的关系[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 178-184.
[13] 钱海舟, 张珊珊, 殷琳玲, 吴智强, 汪露, 杨欢. 经颅多普勒超声在急性前循环大血管闭塞性脑梗死机械取栓后的应用价值[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(01): 61-67.
[14] 张伟东, 刘思婷, 黄蝶, 李永宁. 细胞焦亡介导脑梗死及脑缺血再灌注后脑组织损伤[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(06): 519-525.
[15] 张旭, 唐娟, 申婧, 杨琼, 高沛沛, 田苗苗, 马志翔, 姚恩生. 依达拉奉右莰醇联合阿替普酶动脉溶栓治疗急性脑梗死的临床疗效[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(06): 490-495.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?